- Home
- CINGW vs GNLX Comparison
CINGW vs GNLX Comparison
Compare CINGW & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINGW
- GNLX
- Stock Information
- Founded
- CINGW N/A
- GNLX 2001
- Country
- CINGW United States
- GNLX United States
- Employees
- CINGW 13
- GNLX N/A
- Industry
- CINGW Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CINGW Health Care
- GNLX Health Care
- Exchange
- CINGW Nasdaq
- GNLX Nasdaq
- Market Cap
- CINGW N/A
- GNLX 103.6M
- IPO Year
- CINGW 2021
- GNLX 2023
- Fundamental
- Price
- CINGW $0.04
- GNLX $2.27
- Analyst Decision
- CINGW
- GNLX Strong Buy
- Analyst Count
- CINGW 0
- GNLX 4
- Target Price
- CINGW N/A
- GNLX $18.25
- AVG Volume (30 Days)
- CINGW N/A
- GNLX 142.7K
- Earning Date
- CINGW N/A
- GNLX 11-14-2024
- Dividend Yield
- CINGW N/A
- GNLX N/A
- EPS Growth
- CINGW N/A
- GNLX N/A
- EPS
- CINGW N/A
- GNLX N/A
- Revenue
- CINGW N/A
- GNLX $8,000.00
- Revenue This Year
- CINGW N/A
- GNLX N/A
- Revenue Next Year
- CINGW N/A
- GNLX N/A
- P/E Ratio
- CINGW N/A
- GNLX N/A
- Revenue Growth
- CINGW N/A
- GNLX N/A
- 52 Week Low
- CINGW N/A
- GNLX $1.60
- 52 Week High
- CINGW N/A
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- CINGW N/A
- GNLX 38.68
- Support Level
- CINGW N/A
- GNLX $2.13
- Resistance Level
- CINGW N/A
- GNLX $2.80
- Average True Range (ATR)
- CINGW 0.00
- GNLX 0.20
- MACD
- CINGW 0.00
- GNLX -0.04
- Stochastic Oscillator
- CINGW 0.00
- GNLX 14.21
About CINGW Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.